58.36
-0.85%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Haisco Pharmaceutical Group Co
Its shares trade on Shenzhen under the ticker 002653.SZ. It has been listed since 17 January 2012. In the fiscal year to 31 December 2025, it reported revenue of CN¥4.39bn and net income of CN¥259.6m. At that date it held total assets of CN¥7.01bn and shareholders' equity of CN¥4.29bn.
Haisco Pharmaceutical Group Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products and medical equipment. The company is headquartered in Shannan, Xizang. The company went IPO on 2012-01-17. The Company’s main products are categorized into small volume injections, big volume injections, freeze-dried powder injections and others, which include polyene phosphatidylcholine injections, lipid solubility vitamins injection series, doradiazine methanesulfonate injections, nalmefene hydrochloride injections, fluprofen tromethamine tablets and cefoperazone sodium tazobactam sodium for injections, among others. The firm distributes its products in domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 17 Jan 2012
- Employees
- 4,726
- Website
- haisco.com ↗
Leadership
Pay as last reported
- Mr. Junmin WangChairman of the Board, since 2007CN¥1.8m
- Mr. Peng DuanChief Financial OfficerCN¥1.3m
- Mr. Pangke YanGeneral Manager, Director, since 2021CN¥5.8m
- Mr. Meng WangDeputy General Manager, Secretary of the BoardCN¥1.2m
- Mr. Ruibin WangDeputy General Manager
- Ms. Xiulian FanDirector, since 2007CN¥1.3m
- Mr. Chuande CaoIndependent DirectorCN¥151,400
- Mr. Jun LeIndependent DirectorCN¥151,400
- Ms. Lin YueIndependent DirectorCN¥151,400
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 44
- Environment
- 27
- Social
- 31
- Governance
- 73
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Haisco Pharmaceutical Group employs 4726 employees in Shannan, Xizang for pharmaceutical production.
- The company's main products include small volume injections and freeze-dried powder injections.
- Haisco's product portfolio features polyene phosphatidylcholine injections and cefoperazone sodium tazobactam sodium for injections.
Weaknesses
- Haisco Pharmaceutical Group is headquartered in Shannan, Xizang, a remote location in China.
- The company's business is limited to the domestic market in China.
- Haisco's product range focuses on injections, which may limit market diversity.
Opportunities
- Haisco can expand its product line to include more medical equipment for domestic demand.
- The growing pharmaceutical market in China offers potential for increased sales.
- Haisco may leverage its 2012 IPO to attract investment for new product development.
Threats
- Haisco's reliance on the domestic market exposes it to China's economic fluctuations.
- Competition from other Chinese pharmaceutical companies could impact market share.
- Regulatory changes in China's pharmaceutical industry might affect production and sales.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.